PT-112 Shows Promise for Heavily Treated Myeloma Patients
Phosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy and safety data in an early clinical trial of heavily-pretreated people with relapsed or refractory…
Marisa Wexler, MS, senior science writer — 
Articles by Marisa Wexler
GSK Seeks Ideas for Improving Life in Myeloma Community
A new initiative by GlaxoSmithKline (GSK) is seeking project proposals that will address key needs for people in the multiple myeloma community. Submissions…
CAR T-cell Therapy Cilta-cel Continues to Show Benefits in Heavily Treated Myeloma Patients
Ciltacabtagene autoleucel, an investigational CAR T-cell therapy for multiple myeloma, continues to lead to deep and durable responses in heavily treated patients with relapsed or…
Allogene to Present Positive Phase 1 Data for Investigational CAR T-cell Therapy ALLO-715
ALLO-715, an investigational donor-derived CAR T-cell therapy by Allogene Therapeutics, has a manageable safety profile and promising preliminary efficacy results in people…
Potential Cell Therapy for Multiple Myeloma Named Orphan Drug by FDA
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CellProtect, an investigational therapy for multiple myeloma…
Investigational Myeloma Treatment KP1237 Wins FDA Orphan Drug Status
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kleo Pharmaceuticals‘ KP1237, an investigational treatment for…
First-in-class Blenrep Approved by European Commission for Myeloma
The European Commission (EC) has approved Blenrep (belantamab mafodotin), a first-in-class therapy developed by GlaxoSmithKline (GSK) for the treatment of multiple myeloma.
Darzalex Faspro Combo Shows Benefits for Relapsed, Refractory Myeloma in Phase 3 Trial
Darzalex Faspro (daratumumab and hyaluronidase) significantly extended the time people with relapsed or refractory multiple myeloma live without disease worsening, when added to…
FDA Approves Blenrep, 1st of Its Kind, for Heavily Pretreated Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Blenrep (belantamab mafodotin-blmf), a first-in-class treatment for heavily pretreated adults with…
Celyad to Begin Phase 1 Trial of Donor-derived CAR T-cell Therapy for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has given Celyad Oncology permission to begin a Phase 1 clinical trial of CYAD-211, an…
